Replies to post #806931 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Ex,

How do you feel about the 'symphony'? It is real, is it not?

I don't think the longs here ever dreamed that LP spent over ten years preparing a beautiful 'symphony' for the longs.

Dr. Lana E. Kandalaft is one of members of George Coukos' research group. She used to work at Penn and later moved to Lausanne. Can you believe it? She was the PI of a trial on using DC vaccine in combination with various checking point inhibitors to treat stage IV lung cancer. She published a series papers on DC vaccine and I only listed several for illustration. You would agree that LP should use the data from the trials conducted by the researchers involved in the 'symphony' to strike fantastic deals for the retailers, wouldn't you?

The longs will embrace generational wealth!!!

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
https://www.clinicaltrials.gov/study/NCT01312376

A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer
https://www.nature.com/articles/s43018-023-00623-x

Sara Bobisse, Valentina Bianchi, Janos L. Tanyi, Apostolos Sarivalasis, Edoardo Missiaglia, Rémy Pétremand, Fabrizio Benedetti, Drew A. Torigian, Raphael Genolet, David Barras, Alexandra Michel, Spyridon A. Mastroyannis, Emese Zsiros, Denarda Dangaj Laniti, Zoi Tsourti, Brian J. Stevenson, Christian Iseli, Bruce L. Levine, Daniel E. Speiser, David Gfeller, Michal Bassani-Sternberg, Daniel J. Powell Jr, Carl H. June, Urania Dafni, Lana E. Kandalaft, Alexandre Harari & George Coukos

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity (2023)
https://pubmed.ncbi.nlm.nih.gov/36950115/

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
https://www.tandfonline.com/doi/full/10.4161/onci.22664

Lana E. Kandalaft, Daniel J. Powell, Jr., Cheryl L. Chiang, Janos Tanyi, Sarah Kim, Marnix Bosch, Kathy Montone, Rosemarie Mick, Bruce L. Levine, Drew A. Torigian, Carl H. June & George Coukos
Received 14 Sep 2012, Accepted 25 Oct 2012, Published online: 01 Jan 2013

Vaccines for cancer prevention: exploring opportunities and navigating challenges (2025)
https://pubmed.ncbi.nlm.nih.gov/39622986/

Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development (2023)
https://ascopubs.org/doi/pdf/10.1200/EDBK_391278

The current clinical landscape of personalized cancer vaccines (2022)
https://www.sciencedirect.com/science/article/pii/S0305737222000470

A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy
https://www.nature.com/articles/s41587-024-02420-y

$NWBO

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancerhttps://t.co/SBKW1jVHIQ

The above must be one of the onward trials conducted by Penn after the collaboration trial with $NWBO. Dr. Bosch was listed as one of the coauthors. The really interesting… https://t.co/R0Qj1Z09tW pic.twitter.com/1dW8n4Y6Go

— d_stock (@d_stock07734) January 5, 2026

$NWBO

It is interesting that Study Protocol and Statistical Analysis Plan of a DC vaccine trial conducted by Mayo Clinic was uploaded in June 2021. But the names of all the researchers in the SAP were redacted. Interesting?!

Phase I/II Study of Dendritic Cell Therapy Delivered… pic.twitter.com/4B6geOWg2R

— d_stock (@d_stock07734) January 5, 2026

Vaccine approaches to immune modulation (2023)

New trends in immunotherapy | Georges Coukos & Lana Kandalaft | TEDxCHUV (2014)

Dr. Lana Kandalaft on a Novel Two-Step Immunotherapy for Ovarian Cancer (2013)

Novel Immunotherapy Targets Recurrent Ovarian Cancer (2013)